Literature DB >> 10596901

Mechanisms and therapeutic applications of immune stimulatory cpG DNA.

A M Krieg1, A K Yi, G Hartmann.   

Abstract

Aside from its function as the "blueprint of life" that encodes genetic information, DNA can have direct immune activities. The immune system has evolved a defense mechanism that is able to distinguish microbial DNA from our own because of differences in the frequency and methylation of CpG dinucleotides in particular base contexts. Within minutes of detecting such "CpG-S DNA," cells of the innate immune system become activated and produce cytokines that promote the generation of antigen specific T-helper-1-like immune responses. Animal studies indicate therapeutic utility for CpG-S DNA as a vaccine adjuvant and for the immunotherapy of cancer and infectious and allergic diseases.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10596901     DOI： 10.1016/s0163-7258(99)00023-6

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  9 in total

1.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.

Authors:  Karen A Near; Anthony W Stowers; Dragana Jankovic; David C Kaslow
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages.

Authors:  D K Ghosh; M A Misukonis; C Reich; D S Pisetsky; J B Weinberg
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

4.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 5.  Immunotherapy for lymphomas.

Authors:  John M Timmerman
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

6.  CpG ODN enhances uptake of bacteria by mouse macrophages.

Authors:  P Utaisincharoen; W Kespichayawattana; N Anuntagool; P Chaisuriya; S Pichyangkul; A M Krieg; S Sirisinha
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

7.  CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7).

Authors:  P Utaisincharoen; N Anuntagool; P Chaisuriya; S Pichyangkul; S Sirisinha
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

8.  Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma.

Authors:  Jill A Gershan; Kristen M Barr; James J Weber; Weiqing Jing; Bryon D Johnson
Journal:  J Immunother Cancer       Date:  2015-06-16       Impact factor: 13.751

9.  A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo.

Authors:  Tete Li; Jing Wu; Shan Zhu; Guoxia Zang; Shuang Li; Xinping Lv; Wenjun Yue; Yuan Qiao; Jiuwei Cui; Yan Shao; Jun Zhang; Yong-Jun Liu; Jingtao Chen
Journal:  Front Pharmacol       Date:  2020-02-06       Impact factor: 5.810
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.